Sun Pharmaceutical Industries Ltd. has announced that several new analyses from phase-1 and the pivotal phase-3 clinical trials (reSURFACE 1 and 2) of tildrakizumab, an investigational IL-23p19 inhibitor being evaluated for the treatment of moderate-to-severe plaque psoriasis, will be presented at the 2017 Annual American Academy of Dermatology (AAD) Meeting taking place March 3-7 in Orlando, Florida.

“Not all people with psoriasis respond to currently available therapies or are able to maintain long-term symptom control. We are looking forward to sharing new and continued insights about tildrakizumab at AAD and upcoming meetings,” said Jesper Jensen, executive vice president, biologics and dermatology, Sun Pharma. “With origins in dermatology that stretch back more than 30 years, we are committed to patients suffering from skin conditions. At Sun Dermatology, we care to make a difference.”

Over 1,800 patients across more than 200 clinical sites participated in the tildrakizumab phase-3 pivotal trials (reSURFACE 1 and 2). Data were presented for the first time demonstrating results through 28 weeks of treatment at the European Academy of Dermatology and Venerology (EADV) Congress in October 2016. Regulatory filings for tildrakizumab in the U.S. and Europe are proceeding as planned.

Psoriasis is a chronic immune disease that appears on the skin. It affects an estimated 7.5 million people in the US and approximately 125 million people worldwide1. It is a non-contagious disorder that speeds the growth cycle of skin cells and results in thick scaly areas of skin. The most common form of psoriasis, called plaque psoriasis, appears as red, raised areas of skin covered with flaky white scales, which may be itchy and painful and can crack and bleed2. Despite existing treatment options, many people with plaque psoriasis continue to struggle with the ongoing, persistent nature of this chronic disease.

Tildrakizumab is an investigational humanized, anti-IL-23p19 monoclonal antibody designed to selectively block the cytokine IL-23. With this precise targeting, tildrakizumab has the potential to help control the pathogenic cells responsible for the inflammatory process of psoriasis with limited impact on the rest of the immune system. phase-3 tildrakizumab data provide further evidence for the role of the IL-23 pathway in helping to control the inflammatory process of psoriasis.